The study team, led by researchers from Chengdu Xinjin District People’s Hospital and Sichuan Provincial People’s Hospital, enrolled patients diagnosed according to the FIGO 2018 staging criteria who had undergone chemoradiation, chemotherapy alone, radiation alone, targeted therapy, or no anticancer treatment at all. By drawing on electronic medical records alongside structured patient questionnaires, the investigators assembled a detailed picture of each patient’s disease status, treatment history, and symptom profile. Fatigue was assessed using validated multidimensional instruments, allowing the team to distinguish mild exhaustion from the moderate-to-severe syndrome that most interferes with daily functioning. This dual-source data approach matters because fatigue is notoriously underreported in routine oncology visits, often dismissed by both patients and clinicians as an inevitable consequence of cancer treatment rather than a treatable condition in its own right.

When the researchers ran their multivariate logistic regression, seven independent factors emerged as significant predictors of moderate-to-severe fatigue. Disease stage carried a P value of 0.001, meaning that women with more advanced tumors were substantially more likely to report debilitating exhaustion. Performance status, measured on the Eastern Cooperative Oncology Group scale, was also significant at P = 0.003, reflecting the intuitive but clinically important observation that patients already weakened by their illness are more vulnerable to fatigue. Cancer pain, anemia, and poor appetite each showed even stronger associations, all with P values below 0.001, painting a picture of fatigue as a synergistic symptom cluster rather than an isolated complaint. Perhaps most thought-provoking was the finding that proactive clinician attention to fatigue complaints was independently associated with lower rates of severe fatigue, with P = 0.042, suggesting that the quality of supportive care itself shapes patient outcomes.

The biological logic behind these associations is well supported by the broader literature. Advanced tumor burden drives systemic inflammation, releasing cytokines such as tumor necrosis factor that act directly on the central nervous system to produce the sensation of exhaustion. Anemia reduces oxygen delivery to tissues, compounding the physical cost of every activity, while poor appetite accelerates the catabolic spiral of cancer cachexia, a syndrome whose molecular basis has been increasingly mapped in recent years. Pain disrupts sleep and depletes the physical and psychological reserves patients need to cope with treatment. In other words, the Chinese findings align with a mechanistic model in which fatigue is the downstream product of multiple converging physiological insults, each of which represents a potential point of intervention.

The most eye-catching result, however, concerned Buzhong-Yiqi, a classical herbal formula first codified in the Jin-Yuan dynasty treatises on the spleen and stomach, which in Traditional Chinese Medicine theory is thought to tonify qi and address patterns of internal injury. In the raw comparison between patients who received the formula and those who did not, the BZYQ group showed meaningfully lower symptom scores on independent-sample t-tests and Chi-squared comparisons. But observational data of this kind are always vulnerable to confounding: clinicians may simply prescribe the formula to patients who are less sick to begin with, or conversely to those with more resources and better overall care. To address this, the researchers turned to a statistical technique called propensity-score weighting.

Propensity-score weighting is a method borrowed from causal inference that attempts to simulate the balance of a randomized trial using observational data. Each patient receives a score representing the probability, given her measured baseline characteristics, of having been assigned to the BZYQ group. By weighting patients according to the inverse of these probabilities, the technique creates pseudo-populations in which treated and untreated groups are statistically comparable across the measured covariates, allowing the treatment effect estimate to be freed from the distortion introduced by non-random prescribing. After applying this weighting, the association between BZYQ use and fatigue remained robust: patients in the treated group had a 68.3 percent reduction in the odds of moderate-to-severe cancer-related fatigue, corresponding to an odds ratio of 0.317 with a P value below 0.001.

It is crucial to interpret this number with appropriate scientific caution. This was a retrospective, single-region observational study of 144 patients, not a randomized controlled trial, and propensity-score methods can only adjust for confounders that were measured and recorded. Unmeasured factors, such as differences in social support, adherence, nutritional status, or general health consciousness, could still explain part of the observed association. The authors themselves are careful to frame the finding as preliminary evidence, describing the result as real-world observational data that provides clues for further exploration of the formula’s application value in fatigue management rather than proof of efficacy. Previous systematic reviews of Chinese herbal medicine for cancer-related fatigue have noted the scarcity of high-quality randomized trials, making rigorous prospective testing the obvious next step.

Even setting the herbal question aside, the study carries a clear and actionable message for oncology practice. Cancer-related fatigue is recognized in clinical practice guidelines from both the National Comprehensive Cancer Network and the European Society for Medical Oncology as a syndrome deserving systematic screening and management, yet it remains chronically underassessed in busy clinics. The finding that proactive clinician attention independently predicts better fatigue outcomes suggests that simply asking about exhaustion, taking it seriously, and intervening early may itself change the trajectory of the symptom. The authors argue that fatigue screening should be built into routine care for cervical cancer patients, with long-term dynamic assessment throughout diagnosis and treatment rather than a one-time check at the start of therapy.

The modifiable risk factors identified in the study also offer concrete targets. Cancer pain can be addressed with standardized analgesic protocols, anemia can be monitored and corrected where clinically appropriate, and poor appetite can trigger nutritional support before cachexia takes hold. Each of these interventions is grounded in existing supportive-care guidelines, and each plausibly interrupts one of the converging pathways that produce severe fatigue. For a disease like locally advanced cervical cancer, where treatment itself, whether chemoradiation, platinum-based chemotherapy, or newer immunotherapies and anti-angiogenic agents, imposes a heavy physiological toll, the cumulative benefit of aggressively managing these secondary conditions could be substantial for patients’ quality of life.

Cervical cancer remains a major global health challenge, with GLOBOCAN 2022 estimates placing it among the leading causes of cancer incidence and mortality worldwide, and China bearing a significant share of the burden. As survival improves through combined modality therapy and emerging systemic agents, the spotlight is shifting toward survivorship and the long-term symptoms that erode patients’ daily functioning. This study adds to a growing body of work showing that fatigue is not a trivial side effect but a multifactorial syndrome intertwined with tumor biology, treatment toxicity, and the quality of supportive care. Whether Buzhong-Yiqi ultimately earns a place in evidence-based fatigue management will depend on prospective trials, but the message that half of these patients endure moderate-to-severe exhaustion, and that much of it may be preventable, is one that oncology teams everywhere cannot afford to ignore.

Subject of Research: Prevalence, risk factors, and management of moderate-to-severe cancer-related fatigue in locally advanced cervical squamous cell carcinoma, including its association with Buzhong-Yiqi use

Article Title: Prevalence and independent influencing factors of moderate-to-severe cancer-related fatigue (CRF) and its association with Buzhong-Yiqi (BZYQ) use among patients with locally advanced cervical squamous cell carcinoma (LACSCC): a retrospective observational study using propensity-score weighting (PSW) logistic regression model

Article References: Li, C., Luo, Z., Tian, L., Deng, W., Pang, Q., Bentley, G. T., Luo, Y., & Xie, K. (2026). Prevalence and independent influencing factors of moderate-to-severe cancer-related fatigue (CRF) and its association with Buzhong-Yiqi (BZYQ) use among patients with locally advanced cervical squamous cell carcinoma (LACSCC): a retrospective observational study using propensity-score weighting (PSW) logistic regression model. Supportive Care in Cancer, 34(11), Article 1084. https://doi.org/10.1007/s00520-026-11335-0

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11335-0

Keywords: cancer-related fatigue, cervical cancer, Buzhong-Yiqi, Traditional Chinese Medicine, propensity-score weighting, supportive care, anemia, cancer pain, ECOG performance status, chemoradiation, quality of life, retrospective study